FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2347029403> ?p ?o ?g. }

• W2347029403 endingPage "836" @default.
• W2347029403 startingPage "836" @default.
• W2347029403 abstract "<h3>Importance</h3> Focal cortical dysplasia (FCD), hemimegalencephaly, and megalencephaly constitute a spectrum of malformations of cortical development with shared neuropathologic features. These disorders are associated with significant childhood morbidity and mortality. <h3>Objective</h3> To identify the underlying molecular cause of FCD, hemimegalencephaly, and diffuse megalencephaly. <h3>Design, Setting, and Participants</h3> Patients with FCD, hemimegalencephaly, or megalencephaly (mean age, 11.7 years; range, 2-32 years) were recruited from Pediatric Hospital A. Meyer, the University of Hong Kong, and Seattle Children’s Research Institute from June 2012 to June 2014. Whole-exome sequencing (WES) was performed on 8 children with FCD or hemimegalencephaly using standard-depth (50-60X) sequencing in peripheral samples (blood, saliva, or skin) from the affected child and their parents and deep (150-180X) sequencing in affected brain tissue. Targeted sequencing and WES were used to screen 93 children with molecularly unexplained diffuse or focal brain overgrowth. Histopathologic and functional assays of phosphatidylinositol 3-kinase–AKT (serine/threonine kinase)–mammalian target of rapamycin (mTOR) pathway activity in resected brain tissue and cultured neurons were performed to validate mutations. <h3>Main Outcomes and Measures</h3> Whole-exome sequencing and targeted sequencing identified variants associated with this spectrum of developmental brain disorders. <h3>Results</h3> Low-level mosaic mutations of<i>MTOR</i>were identified in brain tissue in 4 children with FCD type 2a with alternative allele fractions ranging from 0.012 to 0.086. Intermediate-level mosaic mutation of<i>MTOR</i>(p.Thr1977Ile) was also identified in 3 unrelated children with diffuse megalencephaly and pigmentary mosaicism in skin. Finally, a constitutional de novo mutation of<i>MTOR</i>(p.Glu1799Lys) was identified in 3 unrelated children with diffuse megalencephaly and intellectual disability. Molecular and functional analysis in 2 children with FCD2a from whom multiple affected brain tissue samples were available revealed a mutation gradient with an epicenter in the most epileptogenic area. When expressed in cultured neurons, all<i>MTOR</i>mutations identified here drive constitutive activation of mTOR complex 1 and enlarged neuronal size. <h3>Conclusions and Relevance</h3> In this study, mutations of<i>MTOR</i>were associated with a spectrum of brain overgrowth phenotypes extending from FCD type 2a to diffuse megalencephaly, distinguished by different mutations and levels of mosaicism. These mutations may be sufficient to cause cellular hypertrophy in cultured neurons and may provide a demonstration of the pattern of mosaicism in brain and substantiate the link between mosaic mutations of<i>MTOR</i>and pigmentary mosaicism in skin." @default.
• W2347029403 created "2016-06-24" @default.
• W2347029403 creator A5000612576 @default.
• W2347029403 creator A5001220270 @default.
• W2347029403 creator A5001494987 @default.
• W2347029403 creator A5005057454 @default.
• W2347029403 creator A5006527667 @default.
• W2347029403 creator A5006533382 @default.
• W2347029403 creator A5009003042 @default.
• W2347029403 creator A5009712555 @default.
• W2347029403 creator A5009870571 @default.
• W2347029403 creator A5013948006 @default.
• W2347029403 creator A5015187444 @default.
• W2347029403 creator A5015723509 @default.
• W2347029403 creator A5020038458 @default.
• W2347029403 creator A5021605990 @default.
• W2347029403 creator A5021842722 @default.
• W2347029403 creator A5022651744 @default.
• W2347029403 creator A5022967635 @default.
• W2347029403 creator A5025494791 @default.
• W2347029403 creator A5026759277 @default.
• W2347029403 creator A5029028848 @default.
• W2347029403 creator A5037749785 @default.
• W2347029403 creator A5040980763 @default.
• W2347029403 creator A5041026882 @default.
• W2347029403 creator A5041227452 @default.
• W2347029403 creator A5044048476 @default.
• W2347029403 creator A5045529038 @default.
• W2347029403 creator A5048435930 @default.
• W2347029403 creator A5054511522 @default.
• W2347029403 creator A5056424317 @default.
• W2347029403 creator A5057346782 @default.
• W2347029403 creator A5058106214 @default.
• W2347029403 creator A5059626751 @default.
• W2347029403 creator A5059937438 @default.
• W2347029403 creator A5060155908 @default.
• W2347029403 creator A5063843377 @default.
• W2347029403 creator A5064982358 @default.
• W2347029403 creator A5068333465 @default.
• W2347029403 creator A5075068848 @default.
• W2347029403 creator A5078888054 @default.
• W2347029403 creator A5078967801 @default.
• W2347029403 creator A5080910487 @default.
• W2347029403 creator A5083897996 @default.
• W2347029403 creator A5084933406 @default.
• W2347029403 creator A5084979512 @default.
• W2347029403 creator A5090823515 @default.
• W2347029403 date "2016-07-01" @default.
• W2347029403 modified "2023-10-06" @default.
• W2347029403 title "Association of<i>MTOR</i>Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism" @default.
• W2347029403 cites W1483653355 @default.
• W2347029403 cites W1631012263 @default.
• W2347029403 cites W1939528805 @default.
• W2347029403 cites W1969085791 @default.
• W2347029403 cites W1987182404 @default.
• W2347029403 cites W2002000103 @default.
• W2347029403 cites W2004885137 @default.
• W2347029403 cites W2010526426 @default.
• W2347029403 cites W2016910640 @default.
• W2347029403 cites W2039409071 @default.
• W2347029403 cites W2047019441 @default.
• W2347029403 cites W2058433756 @default.
• W2347029403 cites W2063896837 @default.
• W2347029403 cites W2065158705 @default.
• W2347029403 cites W2066914168 @default.
• W2347029403 cites W2068372824 @default.
• W2347029403 cites W2071881327 @default.
• W2347029403 cites W2075566349 @default.
• W2347029403 cites W2079701909 @default.
• W2347029403 cites W2082305496 @default.
• W2347029403 cites W2090549491 @default.
• W2347029403 cites W2093650339 @default.
• W2347029403 cites W2094517081 @default.
• W2347029403 cites W2105727230 @default.
• W2347029403 cites W2111043432 @default.
• W2347029403 cites W2121539587 @default.
• W2347029403 cites W2127063807 @default.
• W2347029403 cites W2132621200 @default.
• W2347029403 cites W2137297899 @default.
• W2347029403 cites W2138044466 @default.
• W2347029403 cites W2143112776 @default.
• W2347029403 cites W254965819 @default.
• W2347029403 doi "https://doi.org/10.1001/jamaneurol.2016.0363" @default.
• W2347029403 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4979321" @default.
• W2347029403 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27159400" @default.
• W2347029403 hasPublicationYear "2016" @default.
• W2347029403 type Work @default.
• W2347029403 sameAs 2347029403 @default.
• W2347029403 citedByCount "204" @default.
• W2347029403 countsByYear W23470294032016 @default.
• W2347029403 countsByYear W23470294032017 @default.
• W2347029403 countsByYear W23470294032018 @default.
• W2347029403 countsByYear W23470294032019 @default.
• W2347029403 countsByYear W23470294032020 @default.
• W2347029403 countsByYear W23470294032021 @default.
• W2347029403 countsByYear W23470294032022 @default.
• W2347029403 countsByYear W23470294032023 @default.
• W2347029403 crossrefType "journal-article" @default.

• next